drugset / Trial / NCT00002847
Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Treatment
Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.
Timeline
- Start
- 1995-09
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | interferon alfa | Protein / enzyme biologic | — | Subcutaneous |